Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
TheBody.com/TheBodyPRO.com covers the 17th Conference on Retroviruses and Opportunistic Infections
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

ART Lowers Heterosexual Transmission Risk

Winter/Spring 2010

Findings from the Partners in Prevention study, presented at CROI (abstract 136) and published in the May 27, 2010, advance issue of The Lancet, indicate that starting combination ART early can reduce the risk of HIV transmission between partners in heterosexual couples. The trial (which was designed to assess whether treating genital herpes could reduce HIV transmission) included more than 3,000 serodiscordant (one positive, one negative) couples in seven sub-Saharan countries.

Advertisement

At study entry, participants had CD4 cell counts above 250 cells/mm3 and were not on ART. During two years of follow-up, 349 HIV positive participants (10%) started ART, half with a CD4 count below 200 cells/mm3, one-third with 200-349 cells/mm3, and 15% with 350 cells/mm3 or higher (including pregnant women receiving antiretroviral drugs to prevent perinatal HIV transmission).

A total of 151 new infections occurred, of which 103 were verified as transmissions within a couple with known ART status, not including perinatal prevention. Of these transmission cases, 102 were from HIV positive participants not taking ART (an incidence rate of 2.24 per 100 person-years). In the absence of treatment, the likelihood of transmission increased as the positive partner's CD4 count decreased (from 8.79 per 100 person-years below 200 cells/mm3 to 1.82 per 100 person-years above 500 cells/mm3).

One transmission, however, was from a person receiving therapy (0.37 per 100 person-years). While ART reduced the risk of transmission by 92%, this single infection demonstrates that treatment does not completely eliminate risk.

Liz Highleyman (liz@black-rose.com) is a freelance medical writer based in San Francisco.


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.
 
See Also
More News and Research on Prevention for the HIV Positive

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement